COMBINATION CHEMOTHERAPY WITH MITOMYCIN-C AND CISPLATIN FOR ADVANCED GASTRIC-CANCER WITH MULTIPLE LIVER METASTASES

被引：4

作者：

SAIKAWA, Y ^{[1
]}

KUBOTA, T ^{[1
]}

FURUKAWA, T ^{[1
]}

KUMAI, K ^{[1
]}

YOSHINO, K ^{[1
]}

ISHIBIKI, K ^{[1
]}

KITAJIMA, M ^{[1
]}

机构：

[1] KEIO UNIV,SCH MED,DEPT SURG,35 SHINANOMACHI,SHINJUKU KU,TOKYO 160,JAPAN

来源：

SURGERY TODAY-THE JAPANESE JOURNAL OF SURGERY | 1994年 / 24卷 / 09期

关键词：

MITOMYCIN-C; CISPLATIN; COMBINATION THERAPY; GASTRIC CANCER; LIVER METASTASIS; ENDOCRINE CELL CARCINOMA;

D O I：

10.1007/BF01636313

中图分类号：

R61 [外科手术学];

学科分类号：

摘要：

A patient with advanced gastric cancer with multiple liver metastases was treated by reduction surgery at the Primary site as well as by the intraarterial administration of mitomycin C (MMC) and cisplatin (CDDP) through a reservoir catheter inserted into the proper hepatic artery. After a palliative subtotal gastrectomy, MMC 8 mg/m2 was administered intraarterially (i.a.) followed by the administration of CDDP 80 or 40 mg/m2 i.a. with an interval of less than 1 week. After the completion of five courses of this regimen, a complete reduction of the hepatic tumors was achieved, while the level of serum carcinoembryonic antigen decreased to the normal range. The patient is currently alive with signs of disease recurrence at 17 months after initial diagnosis, while additional therapy with MMC + CDDP was continuously undergone until 17 months' after initial diagnosis with various interval. Although thrombocytopenia occurred during the treatment, it resolved within a few weeks after completing the combination chemotherapy without any specific treatment. The present case showed a better prognosis than we had expected, which suggested that combination chemotherapy with MMC and CDDP might thus be clinically useful because of its excellent antitumor activity and low toxicity.

引用

页码：819 / 822

页数：4

共 13 条

[1]

Saikawa Y., Kubota T., Kuo T., Kase S., Furukawa T., Tanino H., Ishibiki K., Kitajima M., Synergistic antitumor activity of combination of mitomycin C and cisplatin against gastric cancer in vitro, J Surg Oncol, 54, pp. 98-102, (1993)

[2]

The General Rules for Gastric Cancer Study, (1981)

[3]

Furukawa T., Kubota T., Suto A., Takahara T., Yamaguchi H., Takeuchi T., Kase S., Kodaira S., Ishibiki K., Kitaijima M., Clinical usefulness of chemosensitivity testing using the MTT assay, J Surg Oncol, 48, pp. 188-193, (1991)

[4]

Oken M.M., Creech R.H., Tormey D.C., Horton J., Davis T.E., McFadden E.T., Carbone P.P., Toxicity and response criteria of the Eastern Cooperative Oncology Group, Am J Clin Oncol, 5, pp. 649-655, (1982)

[5]

Koyama Y., Saito T., Criteria for evaluation of the clinical effect of cancer chemotherapy, (1980)

[6]

Solcia E., Capella C., Sessa F., Rindi G., Cornaggia M., Riva C., Villani L., Gastric carcinoids and related endocrine growths, Digestion, 35, pp. 3-22, (1986)

[7]

Yang G.C.H., Rotterdam H., Mixed (composite) glandularendocrine cell carcinoma of the stomach, Am J Surg Pathol, 15, pp. 592-598, (1991)

[8]

Uchida T., Nishikawa K., Shibasaki C., Okamoto K., Arakawa M., Ekimoto H., Takahashi K., Combined effect of CDDP with various types of antitumor drugs against P388 leukemia (in Japanese with English abstract), Jpn J Cancer Chemother, 16, pp. 2275-2282, (1989)

[9]

Durand R.E., Synergism of cisplatin and mitomycin C in sensitive and resistant cell subpopulations of a tumor model, Int J Cancer, 44, pp. 911-917, (1989)

[10]

Albert D.S., Kronmal R., Baker L.H., Stock-Novack D.L., Surwit E.A., Boutsells J.G., Hannigan E.V., Phase-II randomized trial of cisplatin chemotherapy regimens in the treatment of recurrent or metastatic squamous cell cancer of the cervix: a Southwest Oncology Group study, J Clin Oncol, 5, pp. 1791-1795, (1987)

← 1 2 →